In drug sales, the methods of promoting sales must strictly comply with laws and regulations, medical ethics and industry norms to ensure patient safety and information transparency. Even if the efficacy of drugs is limited or controversial, they need to be based on scientific evidence to avoid misleading publicity. The following are some strategies that are compliant and need to be operated with caution： --- ###**1. The core principles of the compliance strategy** 1. **Compliance with regulations**: Strictly abide by the Drug Advertising Law, Anti-unfair Competition Law, medical industry norms, etc., to avoid false publicity or concealment risks. 2. **Scientific basis is preferred**: All promotional content must be based on existing clinical trials or real-world data, with clear indications and limitations. 3. **Transparent communication**: Clearly communicate the actual effects, potential side effects and applicable populations of the drug to doctors and patients. --- ###**2. Compliance promotion methods that can be considered** #### 1. **Accurately locate applicable scenarios** -**Segmented indications**: Focus on specific patient groups where drugs may be effective (such as patients with mild diseases, adjuvant therapy, or specific subtypes), and support the value of their segmented scenarios through data. -**Complementary therapy positioning**: As a supplement to existing therapies, emphasize the role in combination medication or specific stages of the course of the disease. #### 2. **Differentiated competitive advantage** -**Non-curative advantages**: Highlight the convenience of medication (such as once a day), innovative dosage forms (such as oral instead of injection), price advantages, or fewer side effects. -**Optimization of patient experience**: Provide value-added services such as medication reminder tools and disease management apps to improve compliance and satisfaction. #### 3. **Strengthen doctor education and cooperation** -**Evidence-based academic promotion**: Objectively demonstrate the potential value of drugs in specific scenarios through clinical trial data, case analysis, or real-world research. -**Expert endorsement**: Cooperate with authoritative experts in the field to carry out academic conferences or consensus guidelines to clarify the scope of rational use of drugs. -**Accurate delivery of information**: Targeted communication with departments or groups of doctors who may benefit to avoid expanding the promotion of indications. #### 4. **Patient support and education** - **Disease awareness education**: Raise patients' attention to the disease itself through popular science content, and indirectly guide the rational demand for medication. -**Patient assistance plan**: Provide services such as medication supplementation and insurance docking to reduce economic barriers, while emphasizing the need to follow the doctor's instructions for use. #### 5. **Re-mining of data and evidence** -**Real-world research (RWE)**: Collect actual medication data and explore other values other than efficacy disputes (such as improved quality of life, reduced medical costs, etc.). - **Subgroup analysis**: Conduct in-depth analysis of existing clinical trial data to find specific groups of people who may benefit. #### 6. **Brand and trust building** -**Social responsibility marketing**: Enhance brand credibility through public welfare publicity on disease Day, patient community support and other activities. -**Transparent communication**: Take the initiative to disclose the limitations of clinical evidence of drugs and establish the image of a “responsible enterprise”. --- ###**3. Risk behaviors that need to be strictly avoided** 1. **Exaggerate or suggest efficacy**: Avoid absolute expressions such as "radical treatment” and "first choice", or use patient stories to suggest super-indications. 2. **Concealment of risk information**: Contraindications, side effects and uncertainty of efficacy must be clearly marked. 3. **Benefit inducement**: It is forbidden to influence doctors' prescribing decisions through improper means such as rebates and gifts. 4. **Presentation of misleading data**: Do not selectively cite one-sided data or tamper with research conclusions. --- ###**Fourth, long-term suggestions** -**Continuous R&D investment**: Strengthen the scientific evidence base of drugs by improving the formula, expanding indication research or combined drug trials. -**Dynamic risk assessment**: Pay close attention to the monitoring data of drugs after they are marketed, and adjust the promotion strategy in a timely manner to comply with the latest evidence. --- ###**Summary** In the case of limited or controversial efficacy of drugs, the core of promotion should be to accurately convey information in a scientific and transparent manner, focusing on the rational use scenarios and differentiated values of drugs, while strictly observing ethical and legal boundaries. Any strategy should take the interests of patients as the starting point and avoid risky behaviors driven by short-term interests.